BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lakes AL, An DD, Gauny SS, Ansoborlo C, Liang BH, Rees JA, McKnight KD, Karsunky H, Abergel RJ. Evaluating 225Ac and 177Lu Radioimmunoconjugates against Antibody-Drug Conjugates for Small-Cell Lung Cancer. Mol Pharm 2020;17:4270-9. [PMID: 33044830 DOI: 10.1021/acs.molpharmaceut.0c00703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Pallares RM, Flick M, Shield KM, Bailey TA, Velappan N, Lillo AM, Abergel RJ. Development of an actinium-225 radioimmunoconjugate for targeted alpha therapy against SARS-CoV-2. New J Chem . [DOI: 10.1039/d2nj02617a] [Reference Citation Analysis]
2 Ranallo N, Bocchini M, Menis J, Pilotto S, Severi S, Liverani C, Bongiovanni A. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin. Expert Rev Anticancer Ther 2022. [PMID: 35477310 DOI: 10.1080/14737140.2022.2071703] [Reference Citation Analysis]
3 Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight". Pharmaceutics 2021;13:906. [PMID: 34207408 DOI: 10.3390/pharmaceutics13060906] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Jin Y, Edalatian Zakeri S, Bahal R, Wiemer AJ. New Technologies Bloom Together for Bettering Cancer Drug Conjugates. Pharmacol Rev 2022;74:680-711. [PMID: 35710136 DOI: 10.1124/pharmrev.121.000499] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pretze M, Kunkel F, Runge R, Freudenberg R, Braune A, Hartmann H, Schwarz U, Brogsitter C, Kotzerke J. Ac-EAZY! Towards GMP-Compliant Module Syntheses of 225Ac-Labeled Peptides for Clinical Application. Pharmaceuticals (Basel) 2021;14:652. [PMID: 34358076 DOI: 10.3390/ph14070652] [Reference Citation Analysis]
6 Kadassery KJ, King AP, Fayn S, Baidoo KE, MacMillan SN, Escorcia FE, Wilson JJ. H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy. Bioconjug Chem 2022;33:1222-31. [PMID: 35670495 DOI: 10.1021/acs.bioconjchem.2c00190] [Reference Citation Analysis]
7 Mason C, Gimblet GR, Lapi SE, Lewis JS. Novel Tracers and Radionuclides in PET Imaging. Radiol Clin North Am 2021;59:887-918. [PMID: 34392925 DOI: 10.1016/j.rcl.2021.05.012] [Reference Citation Analysis]
8 Xu J, Li S, Xu S, Dai J, Luo Z, Cui J, Cai F, Geng C, Wang Z, Tang X. Screening and Preclinical Evaluation of Novel Radiolabeled Anti-Fibroblast Activation Protein-α Recombinant Antibodies. Cancer Biother Radiopharm 2022. [PMID: 35612467 DOI: 10.1089/cbr.2021.0389] [Reference Citation Analysis]